Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy

Clinical Research in Cardiology

Volumn 101, Issue 6, 2012, Pages 415-426

  Lange, Stefan A ^a   Ebner, Bernd ^b   Wess, Astrid ^a   Kögel, Matthias ^a   Gajda, Mieczyslaw ^c   Hitschold, Thomas ^a   Jung, Jens ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cardiomyopathy; Echocardiography; Mitral valve insufficiency; Trastuzumab therapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GADOLINIUM; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTRAST ENHANCEMENT; DRUG FATALITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART DEATH; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEMODYNAMIC PARAMETERS; HUMAN; IMAGING SYSTEM; MITRAL VALVE REGURGITATION; MONOTHERAPY; MYOCARDITIS; SIDE EFFECT; TREATMENT OUTCOME; ULTRASOUND TRANSDUCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ATRIAL FUNCTION, LEFT; BREAST NEOPLASMS; CARDIOMYOPATHIES; CHEMOTHERAPY, ADJUVANT; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SYSTOLE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84863723945     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0406-0     Document Type: Article

References (62)

1. Boyle P (2005) Breast cancer control: signs of progress, but more work required. Breast 14(6):429-438
2. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK (2008) Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672-1694
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712
5. Hudis CA (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51
6. Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD (1993) ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72(5):801-815
7. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD (1992) Identification of heregulin, a specific activator of p185erbB2. Science 256(5060):1205-1210
8. Marchionni MA, Goodearl AD, Chen MS, Bermingham-Mc- Donogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362(6418):312-318
9. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB (1992) Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69(3):559-572
10. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118(1):84-95
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792
12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N Engl J Med 353(16):1659-1672
14. Meyer D, Birchmeier C (1995) Multiple essential functions of neuregulin in development. Nature 378(6555):386-390
15. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394-398
16. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99(13):8880-8885
17. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459-465
18. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215-1221
19. Ewer MS, Gibbs HR, Swafford J, Benjamin RS (1999) Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26(4 Suppl 12):96-101
20. Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. Circulation 102(3):272-274
21. Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95(7):1592-1600
22. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM, Antman EM, Smith SC, Jr., Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO (2003) ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16(10):1091-1110
23. Dujardin KS, Enriquez-Sarano M, Bailey KR, Nishimura RA, Seward JB, Tajik AJ (1997) Grading of mitral regurgitation by quantitative Doppler echocardiography: calibration by left ventricular angiography in routine clinical practice. Circulation 96(10):3409-3415
24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2(5):358-367
25. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John SM, Stewart W (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79-108
26. Khoo CW, Krishnamoorthy S, Lim HS, Lip GY (2011) Assessment of left atrial volume: a focus on echocardiographic methods and clinical implications. Clin Res Cardiol 100(2):97-105
27. Hummel YM, Klip IJ, de Jong RM, Pieper PG, van Veldhuisen DJ, Voors AA (2010) Diastolic function measurements and diagnostic consequences: a comparison of pulsed wave- and color-coded tissue Doppler imaging. Clin Res Cardiol 99(7):453-458
28. Butz T, Piper C, Langer C, Wiemer M, Kottmann T, Meissner A, Plehn G, Trappe HJ, Horstkotte D, Faber L (2010) Diagnostic superiority of a combined assessment of the systolic and early diastolic mitral annular velocities by tissue Doppler imaging for the differentiation of restrictive cardiomyopathy from constrictive pericarditis. Clin Res Cardiol 99(4):207-215
29. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA (1997) Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30(6):1527-1533
30. Maurer MS, Spevack D, Burkhoff D, Kronzon I (2004) Diastolic dysfunction: can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 44(8):1543-1549
31. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De KG, Leite- Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28(20):2539-2550
32. Yvorchuk KJ, Davies RA, Chan KL (1994) Measurement of left ventricular ejection fraction by acoustic quantification and comparison with radionuclide angiography. Am J Cardiol 74(10):1052-1056
33. Teichholz LE, Cohen MV, Sonnenblick EH, Gorlin R (1974) Study of left ventricular geometry and function by B-scan ultrasonography in patients with and without asynergy. N Engl J Med 291(23):1220-1226
34. Meluzin J, Spinarova L, Bakala J, Toman J, Krejci J, Hude P, Kara T, Soucek M (2001) Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 22(4):340-348
35. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB (1996) Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9(6):838-847
36. Kaul S, Tei C, Hopkins JM, Shah PM (1984) Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 107(3):526-531
37. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John SM, Stewart W (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79-108
38. Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi A, Behrenbeck T, Scott C, Tajik JA, Enriquez- Sarano M (2007) Left atrial remodelling in mitral regurgitation - methodologic approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-echocardiographic and electron beam-computed tomographic study. Eur Heart J 28(14):1773-1781
39. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811-7819
40. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10(1):5
41. Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, Giannarelli D (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109(2):231-239
42. Untch M, Eidtmann H, du BA, Meerpohl HG, Thomssen C, Ebert A, Harbeck N, Jackisch C, Heilman V, Emons G, Wallwiener D, Wiese W, Blohmer JU, Hoffken K, Kuhn W, Reichardt P, Muscholl M, Pauschinger M, Langer B, Luck HJ (2004) Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40(7):988-997
43. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459-465
44. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41(3):389-405
45. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185-229
46. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332-344
47. Chien KR (2006) Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 354(8):789-790
48. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and antierbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13):1551-1554
49. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12
50. Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M (2006) Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48(7):1438-1447
51. Pagel PS, Kehl F, Gare M, Hettrick DA, Kersten JR, Warltier DC (2003) Mechanical function of the left atrium: new insights based on analysis of pressure-volume relations and Doppler echocardiography. Anesthesiology 98(4):975-994
52. Mitchell JH, Shapiro W (1969) Atrial function and the hemodynamic consequences of atrial fibrillation in man. Am J Cardiol 23(4):556-567
53. Castello R, Pearson AC, Lenzen P, Labovitz AJ (1991) Evaluation of pulmonary venous flow by transesophageal echocardiography in subjects with a normal heart: comparison with transthoracic echocardiography. J Am Coll Cardiol 18(1):65-71
54. Prioli A, Marino P, Lanzoni L, Zardini P (1998) Increasing degrees of left ventricular filling impairment modulate left atrial function in humans. Am J Cardiol 82(6):756-761
55. Eshoo S, Ross DL, Thomas L (2009) Impact of mild hypertension on left atrial size and function. Circ Cardiovasc Imaging 2(2):93-99
56. Zhang Q, Kum LC, Lee PW, Lam YY, Wu EB, Lin H, Yip GW, Wu L, Yu CM (2006) Effect of age and heart rate on atrial mechanical function assessed by Doppler tissue imaging in healthy individuals. J Am Soc Echocardiogr 19(4):422-428
57. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D (1995) Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 92(4):835-841
58. Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Kober L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD (2009) Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. Eur Heart J 30(1):56-65
59. Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, Dahlof B, Devereux RB (2007) Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 49(2):311-316
60. Hattori K, Nishi Y, Nakamura S, Misao H, Kikuchi M, Sasaki R, Takeda K (2007) Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography. Rinsho Byori 55(2):120-125
61. Meluzin J, Spinarova L, Bakala J, Toman J, Krejci J, Hude P, Kara T, Soucek M (2001) Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J 22(4):340-348
62. Ghio S, Recusani F, Klersy C, Sebastiani R, Laudisa ML, Campana C, Gavazzi A, Tavazzi L (2000) Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 85(7):837-842